AR018199A1 - 2-quinolinas nh- u o-sustituidas, procedimiento para su preparacion, una composicion farmaceutica que los comprende y el uso de las mismas para lafabricacion de un medicamento - Google Patents

2-quinolinas nh- u o-sustituidas, procedimiento para su preparacion, una composicion farmaceutica que los comprende y el uso de las mismas para lafabricacion de un medicamento

Info

Publication number
AR018199A1
AR018199A1 ARP990101937A ARP990101937A AR018199A1 AR 018199 A1 AR018199 A1 AR 018199A1 AR P990101937 A ARP990101937 A AR P990101937A AR P990101937 A ARP990101937 A AR P990101937A AR 018199 A1 AR018199 A1 AR 018199A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
mono
aryl
amino
Prior art date
Application number
ARP990101937A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9809050.9A external-priority patent/GB9809050D0/en
Priority claimed from GBGB9824571.5A external-priority patent/GB9824571D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR018199A1 publication Critical patent/AR018199A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

2-Quinolinas-NH u O-sustituidas, que comprenden un compuestos de formula (I), en la cual: R1 es arilo opcionalmente sustituido o heteroariloopcionalmente sustituido; R2 es hidrogeno, alquilo C1-6, aril-alquilo C1-4, aril-alquenilo C2-4 o alquil C1-6-carbonilo; R3 se selecciona de halo, ciano,hidroxi, alquilo C1-6 (sustituido opcionalmente con halo, hidroxi, amino, mono o perfluoro-alquilo C1-3, carboxi o alcoxi C1-6-carbonilo), cicloalquiloC3-7, alcoxi C1-6 amino, mono- o di- alquil amino C1-6,acilamino, carboxi, alcoxi C1-6-carbonilo, carboxi-alquiloxi C1-6, alquiltio C1-6, alquilsulfiniloC1-6, alquilsulfonilo C1-6, sulfamoilo, mono- y di- alquil C1-6-sulfamoilo, carbamoilo, mono- ydi- alquil C1-6- carbamoilo, y heterocíclico; m es 0 o unnumero entero de 1 a 3; X es CHR4 (en cuya formula R4 es hidrogeno, alquilo C1-6 o arilo), alquileno C2-4, alquenileno C3-4, o CO; Y es un grupoenlazador que tiene de 2 a 6 grupos metileno en cadena lineal y en el cual uno o más grupos metileno pueden tener uno o más sustituyentesalquilo C1-6, alcoxi C1-6 o alquilidenilo C1-6, y en cuya cadena los átomos de C 1,2 o 1,3 pueden estar enlazados por un puente alquileno C2-3 oalquenileno C3; R1 y X o R1 y R2 pueden estar unidos por una cadena de polimetileno para formar un anillo de 5 a 7 miembros, sustituido opcinalmentecon alquilo C1-6; X y R2, X e Y o Y y R2 pueden estar unidos por una cadena polimetileno para formar un anillo de 4 a 7 miembros, sustituido opcionalmentecon alquilo C1-6; Z esNH u O; y sus sales, preferiblemente sus sales farmacéuticamente aceptables, que son inhibidores de la enzima bactrianametionil-ARNt sintetasa de S aureus y son utiles en el tratamiento de infecciones bacterianas. Además se describe un procedimientopara su preparacion,una composicion farmacéutica que los comprende y el uso de las mismas para la fabricacion de un medicamento.
ARP990101937A 1998-04-29 1999-04-27 2-quinolinas nh- u o-sustituidas, procedimiento para su preparacion, una composicion farmaceutica que los comprende y el uso de las mismas para lafabricacion de un medicamento AR018199A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9809050.9A GB9809050D0 (en) 1998-04-29 1998-04-29 Novel compounds
GBGB9824571.5A GB9824571D0 (en) 1998-11-09 1998-11-09 Novel compounds

Publications (1)

Publication Number Publication Date
AR018199A1 true AR018199A1 (es) 2001-10-31

Family

ID=26313554

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101937A AR018199A1 (es) 1998-04-29 1999-04-27 2-quinolinas nh- u o-sustituidas, procedimiento para su preparacion, una composicion farmaceutica que los comprende y el uso de las mismas para lafabricacion de un medicamento

Country Status (16)

Country Link
US (1) US6320051B1 (es)
EP (1) EP1084110A1 (es)
JP (1) JP2002513005A (es)
KR (1) KR20010043131A (es)
CN (1) CN1307565A (es)
AR (1) AR018199A1 (es)
AU (1) AU3523599A (es)
BR (1) BR9909994A (es)
CA (1) CA2330564A1 (es)
CO (1) CO5080763A1 (es)
HU (1) HUP0103093A3 (es)
IL (1) IL138906A0 (es)
NO (1) NO20005400L (es)
PL (1) PL343680A1 (es)
TR (1) TR200003170T2 (es)
WO (1) WO1999055677A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014121A1 (en) * 1996-04-18 2004-01-22 Smithkline Beecham Corporation Novel compounds
GB9822241D0 (en) * 1998-10-12 1998-12-09 Smithkline Beecham Plc Novel compounds
GB9827467D0 (en) * 1998-12-15 1999-02-10 Zeneca Ltd Chemical compounds
WO2000066120A1 (en) * 1999-05-05 2000-11-09 Merck & Co., Inc. Novel catechols as antimicrobial agents
EP1466603A3 (en) * 1999-05-05 2004-10-20 Merck & Co., Inc. Novel catechols as antimicrobial agents
GB9911594D0 (en) * 1999-05-19 1999-07-21 Smithkline Beecham Plc Novel compounds
AU5213300A (en) * 1999-05-19 2000-12-12 Smithkline Beecham Plc 2-nh-pyridones and pyrimidones as mrs inhibitors
JP2004515507A (ja) * 2000-12-11 2004-05-27 スミスクライン・ビーチャム・コーポレイション ウロテンシン−ｉｉ受容体アンタゴニスト
EP1351688A4 (en) * 2000-12-11 2006-01-04 Smithkline Beecham Corp UROTENSIN-II RECEPTOR ANTAGONISTS
JP2004524295A (ja) * 2001-01-26 2004-08-12 スミスクライン・ビーチャム・コーポレイション ウロテンシン−ｉｉ受容体アンタゴニスト
SE0202134D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
BR0317483A (pt) 2002-12-20 2005-11-16 Glaxo Group Ltd Derivados de benzodiazepina para o tratamento de desordens neurológicas
GB0304809D0 (en) * 2003-03-03 2003-04-09 Glaxo Group Ltd Novel compounds
JP2006519261A (ja) * 2003-03-03 2006-08-24 レプリダイン・インコーポレーテッド 抗菌活性を有する置換されたチオフェン
WO2005009336A2 (en) * 2003-05-01 2005-02-03 Replidyne, Inc. Antibacterial methods and compositions
US20070185079A1 (en) * 2004-01-07 2007-08-09 Astrazeneca Ab Therapeutic agents I
JO3077B1 (ar) * 2005-07-28 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينولين مضادة للبكتيريا
FR2902100A1 (fr) * 2006-06-13 2007-12-14 Sanofi Aventis Sa Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique
US8697720B2 (en) 2006-09-26 2014-04-15 Crestone, Inc. Substituted phenylether-thienopyridone compounds with antibacterial activity
US7973050B2 (en) 2006-09-26 2011-07-05 Crestone, Inc. Enantiomeric compounds with antibacterial activity
US7994192B2 (en) 2006-09-26 2011-08-09 Crestone, Inc. Substituted thienopyridone compounds with antibacterial activity
WO2008039642A2 (en) 2006-09-26 2008-04-03 Replidyne, Inc. Methods and compounds for treatment of clostridium based infection
WO2008039640A2 (en) * 2006-09-26 2008-04-03 Crestone, Inc. Enantiomeric compounds with antibacterial activity
EP2094714B1 (en) * 2006-09-26 2012-08-15 Crestone, Inc. Substituted thienopyridone compounds with antibacterial activity
CN104546857B (zh) * 2013-10-18 2017-01-04 北京北科德源生物医药科技有限公司 化合物naphthoylenequinazolone的抗菌用途
JP7344125B2 (ja) * 2017-03-30 2023-09-13 エフ． ホフマン－ラ ロシュ アーゲー 細菌感染の治療及び予防のための新規ピリド［２，３－ｂ］インドール化合物
CN112870196B (zh) * 2019-11-11 2022-02-18 山东畜牧兽医职业学院 一种治疗耐药性微生物菌的组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005205A (en) * 1974-04-24 1977-01-25 Smith Kline & French Laboratories Limited Compositions and methods for inhibiting H2 histamine receptors
GB8332091D0 (en) * 1983-12-01 1984-01-11 Smith Kline French Lab Chemical compounds
KR950005301B1 (ko) * 1990-09-04 1995-05-23 주식회사대웅제약 신규한 퀴놀론 카르복실산 유도체
KR960007566A (ko) * 1994-08-19 1996-03-22 김정규 신규한 퀴놀릴아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도

Also Published As

Publication number Publication date
HUP0103093A2 (hu) 2002-02-28
CA2330564A1 (en) 1999-11-04
BR9909994A (pt) 2000-12-26
EP1084110A1 (en) 2001-03-21
AU3523599A (en) 1999-11-16
PL343680A1 (en) 2001-08-27
IL138906A0 (en) 2001-11-25
WO1999055677A1 (en) 1999-11-04
TR200003170T2 (tr) 2001-01-22
NO20005400D0 (no) 2000-10-26
HUP0103093A3 (en) 2002-03-28
US6320051B1 (en) 2001-11-20
CO5080763A1 (es) 2001-09-25
JP2002513005A (ja) 2002-05-08
NO20005400L (no) 2000-10-26
KR20010043131A (ko) 2001-05-25
CN1307565A (zh) 2001-08-08

Similar Documents

Publication Publication Date Title
AR018199A1 (es) 2-quinolinas nh- u o-sustituidas, procedimiento para su preparacion, una composicion farmaceutica que los comprende y el uso de las mismas para lafabricacion de un medicamento
CY1108522T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
AR035498A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos, su uso en la preparacion de medicamentos, intermediarios para su preparacion y composiciones farmaceuticas que los contienen
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
AR011093A1 (es) Compuestos derivados de sulfonil urea, composicion farmaceutica que los contiene y procedimiento para su uso.
GEP20063831B (en) Substituted bicyclic derivatives for treatment of abnormal cell growth
ES2194501T3 (es) Derivados de amidinas, su preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
PE20040688A1 (es) Inhibidores de quinasas
BRPI0507652A (pt) composições farmacêuticas compreendendo um derivado de benzoidiazepina e um inibidor da proeìna de fusão de rsv
CR7956A (es) Oxazolidinonas de indolona antibacterial intermedios para su preparacion y composiciones farmaceuticas que contienen los mismos
CY1107446T1 (el) Ανθελμινθικες συνθεσεις
UY30542A1 (es) Formulacion de aerosol para la inhalacion de agonistas beta
DE60024414D1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
AU2505297A (en) Acylated N-hydroxymethyl thalidomide prodrugs having an immunomodulatory effect
HUP0302770A2 (hu) Tripeptidil peptidáz inhibitorok, eljárás az előállítására és ezeket tartalmazó gyógyszerkészítmények
DK0705257T3 (da) Aminosyrederivater som NO-syntaseinhibitorer
DE60226446D1 (de) Zusammensetzungen zur behandlung von neoplastischen krankheiten welche einen cyanoguanidine ikk inhibitor und ein zweites antineoplastisches arzneimittel enthalten
PA8586801A1 (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
AR006833A1 (es) Compuestos de beta lactama monociclicos, composicion farmaceutica que los contiene, uso de dichos compuestos para preparar medicamentos, procedimientopara preparar dichos compuestos, compuestos intermediarios y procedimientos para preparar dichos compuestos intermediarios.
PE20080342A1 (es) Inhibidores de proteasa de hiv de 2-(amino-sustituido)-benzotiazol sulfonamida
WO2006042478A8 (fr) Inhibiteurs de petites molecules de la protease principale des coronavirus, leur preparation et utilisation
ATE206116T1 (de) 6-carboxamido-dihydropyran-derivate
AR043253A1 (es) 4-[(2,4-dicloro-5-metoxifenil)amino] -6- alcoxi-3-quinolina carbonitrilos para el tratamiento de lesiones isquemicas
EA200500683A1 (ru) Новые соединения пирролидина и тиазолидина, способ их получения и фармацевтические композиции, которые их содержат
AR044275A1 (es) Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias